Scientific Publication

Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV infection in Africa in the DART trial

author(s) Grosskurth, H.. - Walker, A.S.. - Kityo, C.. - Gilks, C.F.. - Munderi, P.. - Reid, A.. - Stohr, W.. - Hakim, J.. - Ssali, F.. - Lutwama, F.. - Gibb, D.M.
from UK Foreign, Commonwealth & Development Office (FCDO)
permalink open
themes
regions
  • Eastern Africa
  • Sub-Saharan Africa
  • Africa
  • World
citation

Reid, A.; Stohr, W.; Walker, A.S.; Hakim, J; Ssali, F; Munderi, P; Lutwama, F; Kityo, C.; Grosskurth, H.; Gilks, C.F.; Gibb, D.M. Glomerular dysfunction and associated risk factors through four years following initiation of ART in adults with HIV infection in Africa in the DART trial. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. (2009) 1 pp

Publications and datasets provided via GARDIAN

Abstract

This conference poster presents the results of a study to estimate the prevalence and incidence of a reduction in glomerular filtration rate (GFR), renal serious adverse events and mortality where renal impairment was a contributing factor, together with associated risk factors, through 4-5 years after initiation of antiretroviral therapy. Severe GFR impairment was infrequent on all regimens, chronic kidney disease was only slightly more common. The clinically driven monitoring (CDM) strategy was associated with a severe GFR decrease but not with chronic kidney disease, possibly due to more acute HIV-related events in CDM. Tenofovir DF was associated with minor impairments in kidney function as reported previously, with little clinical significance. Renal disease contributed to death in only a few patients and was generally related to intercurrent disease. Tubular function was not examined in DART

Open original